Atogepant: First Approval

Atogepant (Qulipta (TM)) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries. This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults.

Automated summary

Atogepant is an orally administered CGRP receptor antagonist developed by AbbVie for the prophylaxis of migraine. It has been approved in the USA for preventive treatment of episodic migraine in adults, with ongoing phase 3 clinical development in other countries. This article summarizes the milestones in atogepant's development leading to its first approval for preventive treatment of episodic migraine in adults.